This is the bill as Congress filed it, with every figure linking back to the official record. Say how you\u2019d vote on it before the floor vote happens, and VoteWire will show you what your own representatives did. How it works →
Biosimilars Access and Affordability Act
Latest action (Sep 28, 2026) — on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What it does
not written yetThe Congressional Research Service writes the plain-English summary for every bill, usually a few weeks after it's introduced. This one doesn't have one yet. It will appear here when it does.
In the meantime the most reliable description is the bill's own official title, which is the heading above — written by its sponsor, and the only account of the bill that exists at this stage. The full text is on congress.gov ↗
We don't write our own summaries. Everything else on this site links back to a record you can check, and a description of a bill that came from us rather than from the bill would be the one thing here that didn't — on the page that asks you to take a position on it.
Who lobbied on this
5 organizationsThese organizations told Congress, in their own quarterly disclosures, that they were lobbying on this bill.
- Amgen Inc.no position stated
“…Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.” filing ↗
- Biotechnology Innovation Organizationno position stated
“…---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1954: Biosimilars Red Tape Elimination Act ---Interchangeability and Pharmacy…” filing ↗
- Genentech Inc.no position stated
“…H.R. 10628/S. 5571, Biosimilars Access and Affordability Act” filing ↗
- Merck & Co., Inc.no position stated
“…Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.” filing ↗
- Pharmaceutical Research & Manufacturers of Americano position stated
“H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (Public Law…” filing ↗
Most filings say only that an organization lobbied on a bill, not which side it took — where that's the case we say so rather than guessing. Quotes are verbatim from the filing. How this is built.
Discussion
0 commentsSign in to join the discussion and put your vote on the record.
No comments yet. Be the first to make the case.